



File No. BIO/CT/24/000108

Dated 26-06-2025

To

M/s. CuraTeQ Biologics Private Limited  
Galaxy, Floors: 22-24, Plot No. 1, Survey No: 83/1,  
Hyderabad Knowledge City, Raidurg Panmaktha,  
Ranga Reddy District,  
Hyderabad- 500032, Telangana, India.

Subject: Application for grant of permission to conduct Phase I Clinical trial titled – "Multiple dose study to compare immunogenicity and safety of BP14 (Pegfilgrastim) 6mg/0.6mL solution in single use prefilled syringe and US-Licensed Neulasta (Pegfilgrastim) 6mg/0.6mL solution for injection in healthy adult male subjects" vide protocol No. C1B04735 (sponsor protocol No. BP14-105), Version:01 dated 17.08.2024 – regarding.

Ref.: Your Application No BIO/CT04/FF/2024/45136 dated 29-08-2024.

Sir,

With reference to your Application No. BIO/CT04/FF/2024/45136 dated 29-08-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019. The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:  
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified.
- (XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XIX) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of two years from the date of its issue, unless extended by the Central Licencing Authority.
- (XX) The firm should submit Clinical study report (CSR) to this office after completion of trial.
- (XXI) Firm shall obtain the insurance certificate for the proposed Clinical Trial and copy of the final insurance certificate to be submitted to this office before initiation of Clinical Trial.**

RAJEEV SINGH  
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
Date: 2025.06.30 09:43:16  
+05'30'

Yours faithfully,  
(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)

**FORM CT-06**

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

The Central Licencing Authority hereby permits M/s. CuraTeQ Biologics Private Limited, Galaxy Floors: 22-24, Plot No. 1, Survey No: 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad-500032, Telangana, India to conduct clinical trial of the new drug or investigational new drug study titled – **"Multiple dose study to compare immunogenicity and safety of BP14 (Pegfilgrastim) 6mg/0.6mL solution in single use prefilled syringe and US-Licensed Neulasta (Pegfilgrastim) 6mg/0.6mL solution for injection in healthy adult male subjects" vide protocol No. C1B04735 (sponsor protocol No. BP14-105), Version:01 dated 17.08.2024** in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 26.06.2025

**RAJEEV SINGH**

**RAGHUVANSHI**

Digitally signed by RAJEEV  
SINGH RAGHUVANSHI

Date: 2025.06.30 09:43:31  
+05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Central Licensing Authority

**Annexure:****Details of new drug or investigational new drug:**

Name of the new drug or investigational new drug	Pegfilgrastim Injection 6mg PFS		
Therapeutic class	Immunostimulants		
Dosage form:	Solution for injection		
Composition:	Each 0.6ml single-dose prefilled syringes contains pegfilgrastim 6mg (10mg/ml)		
	Name of Ingredient	Function	Quantity per 300mcg/0.5ml PFS
	Pegfilgrastim (rDNA origin) IH	Active ingredient	6 mg
	Polysorbate 20 Ph.Eur.	Stabilizer	0.024 mg
	Glacial Acetic Acid Ph.Eur.	Buffering agent	0.35 mg
	Sodium Hydroxide Ph.Eur.	pH adjustment	0.034 mg
	Sorbitol Ph.Eur.	Tonicity agent	30 mg
	Water for Injection USP-NF, Ph.Eur.	Diluent	q.s. to 0.6 mL
Indications:	Febrile neutropenia		

**Details of clinical trial site:**

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Cliantha Research Limited, Cliantha Corporate, TP 86, FP 28/1, Off S.P. Ring Road, Sarkhej, Ahmedabad-382210, Gujarat, India	Riddhi Medical Nursing Home Institutional Ethics Committee A/101, Jalaram Plaza, Jawahar Chowk, Maninagar, Ahmedabad-380 008, Gujarat, India <u>EC Reg. No.</u> ECR/886/inst/GJ/2016/RR-16.	Dr. Dhruv Patel